Health · 3 views
ACAAI: Considerable delay seen from Rx to approval for children's biologics
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual…
Summary
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- No oxygen? Chicken brain cells still surviveContinue reading
- Researchers find potential way to protect the brain from HIV and opioid damageContinue reading
- Liver cells activate scarring-linked genes in stiff surroundings but favor repair signals in softer conditionsContinue reading
- How Impactful Is Stock Epinephrine for Anaphylaxis at Schools?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow